Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.
You may also be interested in...
EMA Warning For Ariad’s Iclusig, While CHCs Get The Benefit Of The Doubt
EMA doesn’t suspend, but warns on Ariad’s leukemia drug Iclusig for potential blood clots, while saying combined hormonal contraceptives’ benefit outweighs their risk.
Biotech IPO Candidates Ramp Up To Get Out Before The Holidays
After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.
AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia
Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.